An interventional study of mindfulness in Mindfulness and Alzheimer's Disease Related Dementia, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-11.
Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Alzheimer Disease by Washington University School of Medicine — 8 open to participants now, 15 under way, 5 of them phase 3. Alzheimer Disease · Washington University School of Medicine.
Among the 25 studies in Alzheimer Disease by Washington University School of Medicine, this one is the 11th largest by planned enrollment of the 14 interventional ones that give a count, is one of 5 that started in 2024, is one of 5 with no phase, reaches primary completion later than 1 of the 14 other live ones, and was the 23rd registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →8 of the 25 studies in Alzheimer Disease by Washington University School of Medicine are open now, in 12 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States, Argentina, Australia and 12 more countries
Ages 18+ · Healthy volunteers
Washington University School of Medicine · Sites in United States, Argentina, Australia and 11 more countries
Ages 18+ · Healthy volunteers
Washington University School of Medicine · Sites in United States
Ages 60+ · Healthy volunteers
Washington University School of Medicine · Sites in United States
Ages 18+ · Healthy volunteers
Washington University School of Medicine · Sites in United States
Ages 50+ · Healthy volunteers
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 7
First in 2009; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 232 across the 14 interventional studies, 96 across the 11 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Washington University School of Medicine is the lead sponsor of 1,806 studies on the registry; 271 are open to participants now.
Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.
4 of the studies in Alzheimer Disease by Washington University School of Medicine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06439992Washington University School of MedicineBeta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl | 2026-12 |
| NCT02414178Washington University School of MedicineF 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project) | 2027-01 |
| NCT06129838Washington University School of MedicineInvestigation of Inflammation in Alzheimer's Disease and Related Dementias (ADRD) Using [11C]-CS1P1 | 2027-05 |
| NCT05464368Washington University School of MedicineR21 Roche: 3-Way Tau Tracers in AD | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 25 studies in Alzheimer Disease by Washington University School of Medicine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the proposed research is to investigate the promise and underlying mechanisms of mindfulness training as a preventative lifestyle intervention to enhance cognitive health in Latino older adults, thereby mitigating risk of Alzheimer's Disease (AD) in a population that may be particularly vulnerable.
This proposal rigorously examines the feasibility and mechanisms of action of a novel, culturally-sensitive mindfulness training program developed by the PIs, utilizing EEG methods and theoretically-optimized cognitive control tasks to assess neurocognitive effects. Additionally, blood-based assessment of AD biomarkers will be utilized to test whether biomarker status will moderate the effect of training, such that the neurocognitive benefits will be larger Latino older adults with greater evidence of AD-related pathology. Furthermore, the study will also seek to elucidate the subjective effects of mindfulness training on daily-life experiences using ecological momentary assessment (EMA) methods. The study will utilize a mixed between and within-subject design involving longitudinal (pre vs. post-training) assessment and a wait-list control group. 60 Latino older adults will first complete a baseline assessment protocol, followed by randomized assignment to either the mindfulness or wait-list group (N=30 in each group). The mindfulness group will receive 8 weeks of mindfulness training. During this 8-week period participants from both groups will also complete an EMA protocol, consisting of prompts occurring 4x/day on 3 random days per week, assessing subjective mindfulness states, practice experiences, mood, cognition, setting, and activity. Both groups will then return to repeat performance of the same assessment protocol. The assessment protocol involves two testing sessions performed on separate days, each involving completion of the Stroop and AX-CPT task while continuous EEG is recorded. The mindfulness training curriculum utilizes a novel adaptation of the well-validated mindfulness-based stress reduction (MBSR) course, that has been previously validated in focus groups. Participants will meet weekly with an instructor (either in-person or on-line) in classes to receive instructions and practice mindfulness skills. The curriculum embeds core MBSR principles and practices within a culturally-sensitive didactic framework, that includes four key modifications: (1) delivering all instruction in participants native Spanish language; (2) emphasizing/encouraging the connection between mindfulness practices and participants' personal religious beliefs (e.g., "connecting the breath/body to God"), (3) incorporating culturally unique experiences into group activities/exercises (e.g., sharing immigration stories and examining how alterations in perspective can influence meaning and affect), and (4) adding more familial focus to course content (e.g., highlighting how certain skills or practices can benefit the family). In addition to weekly class meetings, participants will also have access to instructional videos and guided audio practices available on their mobile device; on these devices, they will also be periodically prompted to partake in a short mindfulness behavioral task, a 2-minute breath-counting exercise. Finally, all participants will complete a blood draw at the end of the study to determine AD biomarker status. Outcomes will be assessed using EMA measures of daily mindfulness and mood/cognition as well as other qualitative self-report measures assessing the accessibility, utility and feasibility of the mindfulness training curriculum (Aim 1); EEG/ERP measures of state mindfulness and neurocognitive functioning (Aim 2); behavioral metrics of cognitive performance (Aim 2); and moderating role of AD biomarker status (Aim 3).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MBSR: Mindfulness Program A novel and culturally-adapted version of the well-validated mindfulness-based stress reduction (MBSR) course will be used for the intervention. The adapted program curriculum embeds core MBSR principles and practices within a culturally responsive didactic framework developed directly from community focus-group feedback. The course will be delivered via a group meeting across 8 weeks, with weekly classes held at a local community center. All classes will be held in hybrid format, with most participants attending in person, but with a live-stream option offered via Zoom.
EEG brain markers of cognitive functioning
EEG indices of cognitive performances evoked by task stimuli and participant responses. ERP components of attention and cognitive control during task performance, focused on target-related P3 amplitude.
Time frame: Time-frame: 2 time-points - baseline/pre-intervention, and immediately after the intervention
EEG brain markers of cognitive functioning
EEG indices of cognitive performances evoked by task stimuli and participant responses. ERP components of attention and cognitive control during task performance, focused on cue-related Contingent Negative Variation (CNV).
Time frame: Time-frame: 2 time-points - baseline/pre-intervention, and immediately after the intervention
AXCPT behavioral performance (reaction time)
Behavioral performance indices during AXCPT task: AX-CPT - reaction time in milliseconds
Time frame: Assessed at 2 timepoints: baseline/pre-intervention immediately post-intervention
AXCPT behavioral performance score (accuracy)
Behavioral performance indices during AXCPT task: AX-CPT - % accuracy AX-CPT --% accuracy
Time frame: Assessed at 2 timepoints: baseline/pre-intervention immediately post-intervention
Five Facet Mindfulness Questionnaire (FFMQ) score
Five Facet Mindfulness Questionnaire (FFMQ) is a 39-item self-report inventory used to measure five distinct facets of mindfulness. The five facets are observing, describing, acting with awareness, non-judging of inner experience, and non-reactivity to inner experience, each rated on a 5-point Likert scale.
Time frame: Performed during the intervention (3x /week for 8 weeks)
The Mindful Attention Awareness Scale (MAAS) score
The Mindful Attention Awareness Scale (MAAS) is a 15-item measure of mindfulness that prioritizes assessment of the general tendency to be attentive and aware of experiences in the present moment. It is is rated on a 6-point Likert scale (almost always, very frequently, somewhat frequently, somewhat infrequently, very infrequently, almost never).
Time frame: Performed during the intervention (3x /week for 8 weeks)
Cognitive and Affective Mindfulness Scale (CAMS-R) score
Cognitive and Affective Mindfulness Scale (CAMS-R) is used to evaluate symptoms of mindfulness as EMA (ecological momentary assessment) questions. It will be measured in a Likert scale (Not at all, Somewhat, Quite a bit, Almost completely)
Time frame: Performed during the intervention (3x /week for 8 weeks)
Patient-Reported Outcomes Measurement Information System (Promis) score
PROMIS (Patient-Reported Outcomes Measurement Information System) are item banks that measure common health outcomes across the domains of physical, mental, and social health.
Time frame: Performed during the intervention (3x /week for 8 weeks)
National Institutes of Health Toolbox Emotion Battery (NIH-TOOLBOX-EB) score
National Institutes of Health Toolbox Emotion Battery for English- and Spanish-speaking adults (NIH-TOOLBOX-EB): National Institutes of Health Toolbox Emotion Battery for English- and Spanish-speaking adults (NIH-TOOLBOX-EB) A series of scales that will be rated on a 5-point Likert scale which include: 1. General Life Satisfaction 2. Meaning and Purpose 3. Loneliness 4. Sadness 5. Positive Affect 6. Fear Affect 7. Perceived Stress 8. Resilience Scale 9. Sleep Quality Scale
Time frame: baseline (pre-intervention) & immediately post-intervention
EEG metrics of mindfulness practice quality
EEG spectral power (alpha, theta bands) evoked during guided mindfulness state induction
Time frame: Assessed at 2 timepoints: baseline/pre-intervention immediately post-intervention
Plan to share: Yes — All of the data collected in will be preserved through deposition in a public access data repository (i.e., Open Science Framework [OSF]). Raw self-report, transcription, and EMA data will be recoded, scored, and wrangled to "long" format to enhance accessibility and ease of use prior to sharing. All shared data will be deidentified.
Supporting information: Statistical analysis plan, Analytic code
Time frame: Data will be made available one year after data collection begins and updated annually until the award period ends. All data, data wrangling procedures, registrations, and analysis scripts associated with published manuscripts will be organized into an easily accessible subfolder and made available no later than the time of publication acceptance. The data will be available for public access indefinitely, or until new guidelines are released regarding data archival duration.
Access criteria: All data that is uploaded to OSF will be publicly available with no controlled access.
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Jul 2026, 19 months after the start.
Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 19 months is below that.
Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Washington University School of Medicine →